Back to News
Market Impact: 0.4
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Source: zacks.com
Legal & LitigationHealthcare & BiotechCompany Fundamentals
Liquidia settled six legal disputes with United Therapeutics, securing Yutrepia access for patients with pulmonary arterial hypertension (PAH). The settlement requires $380.7 million in payments and leaves Yutrepia with a narrower drug label, offsetting the benefit of resolving the disputes and securing access.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
LQDA0.10
UTHR0.30
More News
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- US Stocks Tumble as Chip Rout Deepens
- Bank of America Has 'Accountability' in Face of Fines, Says Moynihan
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements
- AI Tools for Independent Research Firms: A Publishing System